---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-091097"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:13:36.347904+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocugen-Carisma merger terminated after Ocugen failed to secure $25M investment

## Summary
- Carisma terminated Merger Agreement on Sep 16, 2025 because Ocugen obtained less than $25M in commitments for the Concurrent Investment.
- Ocugen attributes difficulty to poor market conditions and the tight timeline before Carisma's Nasdaq compliance deadline of Oct 7, 2025.
- Ocugen will focus on gene therapies and continue exploring other options for its regenerative cell therapy platform, including NeoCart.

## SEC filing metadata
- accession: 0001104659-25-091097
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465925091097/0001104659-25-091097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465925091097/tm2526448d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-091097
- JSON: https://secwatch.observer/filing/0001104659-25-091097.json
- Plain text: https://secwatch.observer/filing/0001104659-25-091097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.